PMID- 24462873 OWN - NLM STAT- MEDLINE DCOM- 20140430 LR - 20211203 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 444 IP - 2 DP - 2014 Feb 7 TI - Effect of adiponectin on cardiac beta-catenin signaling pathway under angiotensin II infusion. PG - 224-9 LID - S0006-291X(14)00067-9 [pii] LID - 10.1016/j.bbrc.2014.01.043 [doi] AB - Obesity is associated with heart failure and cardiac hypertrophy. Adiponectin has been shown to play a protective role for cardiovascular diseases. The beta-catenin signaling pathway is deeply involved in cardiac hypertrophy. However, the effect of adiponectin on beta-catenin signaling has not been investigated in cardiac hypertrophy. Present study aimed to clarify the involvement of adiponectin and beta-catenin signaling pathway in the mouse model of angiotensin II (AngII)-induced cardiac hypertrophy. In hearts of Wild type (WT) mice, AngII dose-dependently augmented cytosolic beta-catenin protein level. WT and adiponectin knockout (Adipo-KO) mice were administered with AngII at 2.4 mg/kg/day for 14 days and were also injected with adenovirus expressing the adiponectin (Ad-Adipo) or the beta-galactosidase (Ad-betagal). Cardiac mRNA levels relating to hypertrophy and beta-catenin signaling were increased in Adipo-KO mice and these changes were reversed by Ad-Adipo. Phosphorylation of Akt was increased in Adipo-KO mice and such increases were reversed by Ad-Adipo. Furthermore, the phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser(9) and cytosolic beta-catenin level were increased in Adipo-KO mice and they were significantly reduced by Ad-Adipo treatment. Phosphorylation of mammalian target of rapamycin (mTOR) was reduced by Ad-Adipo-mediated adiponectin supplementation in WT and Adipo-KO mice. The current study suggests that adiponectin attenuates AngII-induced cardiac hypertrophic signals partly through Akt/GSK3beta/beta-catenin and Akt/mTOR pathways. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Fujishima, Yuya AU - Fujishima Y AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Maeda, Norikazu AU - Maeda N AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. Electronic address: norikazu_maeda@endmet.med.osaka-u.ac.jp. FAU - Matsuda, Keisuke AU - Matsuda K AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Komura, Noriyuki AU - Komura N AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Hirata, Ayumu AU - Hirata A AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan; Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Mori, Takuya AU - Mori T AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Sekimoto, Ryohei AU - Sekimoto R AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Tsushima, Yu AU - Tsushima Y AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Nishizawa, Hitoshi AU - Nishizawa H AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Funahashi, Tohru AU - Funahashi T AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan; Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. FAU - Shimomura, Iichiro AU - Shimomura I AD - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2-B5 Yamada-oka, Suita, Osaka 565-0871, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140122 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Adiponectin) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (beta Catenin) RN - 11128-99-7 (Angiotensin II) RN - EC 2.7.1.1 (mTOR protein, mouse) RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta) RN - EC 2.7.11.1 (Gsk3b protein, mouse) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 2.7.11.26 (Glycogen Synthase Kinase 3) SB - IM MH - Adenoviridae/genetics MH - Adiponectin/genetics/*metabolism MH - Angiotensin II/administration & dosage MH - Animals MH - Cardiomegaly/chemically induced/genetics/*metabolism MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Female MH - Gene Expression/drug effects MH - Glycogen Synthase Kinase 3/metabolism MH - Glycogen Synthase Kinase 3 beta MH - Immunoblotting MH - Infusion Pumps, Implantable MH - Mice MH - Mice, Knockout MH - Myocardium/metabolism MH - Phosphorylation MH - Proto-Oncogene Proteins c-akt/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - *Signal Transduction MH - TOR Serine-Threonine Kinases/metabolism MH - beta Catenin/*metabolism OTO - NOTNLM OT - Adiponectin OT - Angiotensin II OT - Cardiac hypertrophy OT - beta-catenin EDAT- 2014/01/28 06:00 MHDA- 2014/05/03 06:00 CRDT- 2014/01/28 06:00 PHST- 2013/12/20 00:00 [received] PHST- 2014/01/14 00:00 [accepted] PHST- 2014/01/28 06:00 [entrez] PHST- 2014/01/28 06:00 [pubmed] PHST- 2014/05/03 06:00 [medline] AID - S0006-291X(14)00067-9 [pii] AID - 10.1016/j.bbrc.2014.01.043 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2014 Feb 7;444(2):224-9. doi: 10.1016/j.bbrc.2014.01.043. Epub 2014 Jan 22.